652 related articles for article (PubMed ID: 36420275)
1. Post-vaccination SARS-CoV-2 seroprevalence in children aged 3-11 years and the positivity in unvaccinated children: A retrospective, single-center study.
Li J; Ge M; Dai S; Song Q; Liu W; Wang Y; Xu W; Ma L
Front Immunol; 2022; 13():1030238. PubMed ID: 36420275
[TBL] [Abstract][Full Text] [Related]
2. Pediatric population (aged 3-11 years) received primary inactivated SARS-CoV-2 vaccination prior to infection exhibiting robust humoral immune response following infected with Omicron variant: a study conducted in Beijing.
Li J; Li J; Dai S; Dang L; Wang L; Cao L; Chen X; Wang Y; Ge M; Liu W; Song Q; Xu W; Ma L
Front Immunol; 2023; 14():1269665. PubMed ID: 37828994
[TBL] [Abstract][Full Text] [Related]
3. Are SARS-CoV-2 Antibodies Detectable in Human Milk After Vaccination Against COVID-19?
Scaggs Huang F
J Pediatric Infect Dis Soc; 2022 Apr; 11(4):126. PubMed ID: 35394545
[TBL] [Abstract][Full Text] [Related]
4. SARS-CoV-2 serology in pediatrics: Seroprevalence studies in unvaccinated children and humoral antibody response post vaccination.
Bohn MK; Steele S; Adeli K
Clin Biochem; 2023 Sep; 119():110630. PubMed ID: 37549823
[TBL] [Abstract][Full Text] [Related]
5. Seroprevalence of anti-SARS-CoV-2 IgG antibodies pre- and post-COVID-19 vaccination in staff members of Bandar Abbas Children's Hospital.
Tariverdi M; Mohammadi H; Hassanzadeh F; Tamaddondar M
BMC Infect Dis; 2024 Feb; 24(1):253. PubMed ID: 38395759
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Kinetics of SARS-CoV-2 Antibodies and Impact of Inactivated Vaccine on SARS-CoV-2 Antibodies Based on a COVID-19 Patients Cohort.
Zhang S; Xu K; Li C; Zhou L; Kong X; Peng J; Zhu F; Bao C; Jin H; Gao Q; Zhao X; Zhu L
Front Immunol; 2022; 13():829665. PubMed ID: 35154152
[TBL] [Abstract][Full Text] [Related]
7. [Humoral Immune Response in Inactivated SARS-CoV-2 Vaccine: When Should a Booster Dose be Administered?].
Kara E; Tanır F; Demirhindi H; Mete B; Kibar F; Çetiner S; Candevir A; İnaltekin A
Mikrobiyol Bul; 2022 Jul; 56(3):566-573. PubMed ID: 35960246
[TBL] [Abstract][Full Text] [Related]
8. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
Front Immunol; 2022; 13():827306. PubMed ID: 35173736
[TBL] [Abstract][Full Text] [Related]
9. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
Front Immunol; 2021; 12():802858. PubMed ID: 35003131
[TBL] [Abstract][Full Text] [Related]
10. [Change in serum IgG antibody during the recovery stage of Omicron variant infection in children: an analysis of 110 cases].
Zhang PP; Guo YT; Chu YQ; Ji QI; Lian Y; Li W; Yao LN
Zhongguo Dang Dai Er Ke Za Zhi; 2022 Jul; 24(7):736-741. PubMed ID: 35894186
[TBL] [Abstract][Full Text] [Related]
11. High SARS-CoV-2 infection rate in children unvaccinated with COVID-19 vaccine in Changzhou, China, shortly after lifting zero-COVID-19 policy in December 2022.
Tang J; Wang Y; Lu W; Gao Z; Xu M; Wu L; Jin J
BMC Infect Dis; 2024 Jun; 24(1):560. PubMed ID: 38840046
[TBL] [Abstract][Full Text] [Related]
12. Longitudinal antibody response kinetics following SARS-CoV-2 messenger RNA vaccination in pregnant and nonpregnant persons.
Prabhu M; Yang YJ; Johnston CD; Murphy EA; Ketas TJ; Diaz-Tapia R; Jurkiewicz M; Racine-Brzostek S; Mohammed I; Sukhu AC; Singh S; Forlenza K; Iyer S; Yee J; Eng D; Marks K; Zhao Z; Klasse PJ; Permar S; Moore JP; Riley LE
Am J Obstet Gynecol MFM; 2023 Feb; 5(2):100796. PubMed ID: 36334723
[TBL] [Abstract][Full Text] [Related]
13. A longitudinal seroepidemiology study to evaluate antibody response to SARS-CoV-2 virus infection and vaccination in children in Calgary, Canada from July 2020 to April 2022: Alberta COVID-19 Childhood Cohort (AB3C) Study.
Doucette EJ; Gray J; Fonseca K; Charlton C; Kanji JN; Tipples G; Kuhn S; Dunn J; Sayers P; Symonds N; Wu G; Freedman SB; Kellner JD
PLoS One; 2023; 18(4):e0284046. PubMed ID: 37023007
[TBL] [Abstract][Full Text] [Related]
14. Association of Gestational Age at Coronavirus Disease 2019 (COVID-19) Vaccination, History of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection, and a Vaccine Booster Dose With Maternal and Umbilical Cord Antibody Levels at Delivery.
Yang YJ; Murphy EA; Singh S; Sukhu AC; Wolfe I; Adurty S; Eng D; Yee J; Mohammed I; Zhao Z; Riley LE; Prabhu M
Obstet Gynecol; 2022 Mar; 139(3):373-380. PubMed ID: 34963127
[TBL] [Abstract][Full Text] [Related]
15. Seroprevalence of IgM and IgG Against SARS-CoV-2 after Two Doses of Pfizer-BioNTech COVID-19 Vaccine in Women with Breast Cancer.
Almehmadi M; Salih MM; Shafie A; Alsharif A; Alsiwiehr N; El-Askary A; Alzahrani K; Al-Hazmi A; Aljuaid A; Abdulazziz O; Almalki AA; Allahyani M; Eed E; Alharbi AM; Halawi M; Allam HH; Abutawil H; Alosimi E; Gharib AF
Clin Lab; 2022 Nov; 68(11):. PubMed ID: 36378000
[TBL] [Abstract][Full Text] [Related]
16. Maternal and Neonatal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Immunoglobulin G Levels After the Pfizer-BioNTech Booster Dose for Coronavirus Disease 2019 (COVID-19) Vaccination During the Second Trimester of Pregnancy.
Kugelman N; Nahshon C; Shaked-Mishan P; Kleifeld S; Cohen N; Sher ML; Zahran H; Barsha H; Assaf W; Shalabna E; Stein N; Lavie O; Kedar R; Riskin-Mashiah S
Obstet Gynecol; 2022 Aug; 140(2):187-193. PubMed ID: 35852268
[TBL] [Abstract][Full Text] [Related]
17. Human IgM and IgG Responses to an Inactivated SARS-CoV-2 Vaccine.
Banga Ndzouboukou JL; Zhang YD; Lei Q; Lin XS; Yao ZJ; Fu H; Yuan LY; Fan XL
Curr Med Sci; 2021 Dec; 41(6):1081-1086. PubMed ID: 34741251
[TBL] [Abstract][Full Text] [Related]
18. Immunoassay and mass cytometry revealed immunological profiles induced by inactivated BBIBP COVID-19 vaccine.
Cheng ZJ; Huang H; Liu Q; Zhong R; Liang Z; Xue M; Liu M; Li S; Wang H; Zheng P; Zheng C; Sun B
J Med Virol; 2022 Nov; 94(11):5206-5216. PubMed ID: 35801663
[TBL] [Abstract][Full Text] [Related]
19. High seroprevalence of Immunoglobulin G (IgG) and IgM antibodies to SARS-CoV-2 in asymptomatic and symptomatic individuals amidst vaccination roll-out in western Kenya.
Awandu SS; Ochieng Ochieng A; Onyango B; Magwanga RO; Were P; Atieno Ochung' A; Okumu F; Oloo MA; Katieno JS; Lidechi S; Ogutu F; Awuor D; Kirungu JN; Orata F; Achieng J; Oure B; Nyunja R; Muok EMO; Munga S; Estambale B
PLoS One; 2022; 17(12):e0272751. PubMed ID: 36548358
[TBL] [Abstract][Full Text] [Related]
20. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
